Fluorescent cytotoxic compounds specific for the cellular polyamine transport system

Patent metadata

Field	Value
Publication number	US-9285320-B2
Application number	US-201313835708-A
Country	US
Kind code	B2
Filing date	Mar 15, 2013
Priority date	May 1, 2008
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

Cyano-substituted anthracene containing polyamines were synthesized and shown to be efficient polyamine transporter ligands. Moreover, these compounds (3 and 4) had improved fluorescence properties over previously known anthryl-polyamine conjugates, which facilitated their intracellular trafficking by confocal microscopy and fluorescence methods. These cytotoxic fluorescent agents may find use as molecular probes which traffic into cells via the polyamine transport system and may also be viable anticancer drugs which are readily quantified in human tissues due to their excellent fluorescence properties: (excitation: λ 405 nm) and emission (420 nm) occurs in the visible light range. The ability to excite and emit in the visible range provides an advantage to these probes as these wavelengths are considered non-toxic to human cells (versus ultraviolet mediated excitations, λ<400 nm) and visible light lasers are less costly to purchase and operate than UV laser sources.

First claim

The invention claimed is:

1. A method of screening for cells or cell lines that are susceptible to a polyamine transport system targeting strategy, the method comprising:
contacting at least one test cell with a fluorescent cyano-substituted anthracene probe, wherein the probe is selected from the group consisting of compound 3 and compound 4

incubating the at least one test cell and the probe for a time sufficient for the probe to be internalized within the at least one test cell;
exciting the probe using a visible light source; and
determining whether the probe is internalized by the at least one test cell;
wherein a test cell that internalizes the probe is identified as a cell that is susceptible to a polyamine transport system targeting strategy.

2. The method of claim 1 , further comprising washing the at least one test cell to remove unbound probe after the contacting step.

3. The method of claim 1 , wherein the probe comprises compound 3

4. The method of claim 1 , wherein the probe comprises compound 4

5. The method of claim 1 , wherein the at least one test cell is a known cancerous cell.

6. The method of claim 1 , wherein the probe is excited at a wavelength of at least 400 nm.

7. The method of claim 1 , wherein the probe has an emission wavelength in the visible light range.

8. The method of claim 7 , wherein the probe has an emission wavelength at 420 nm.

9. The method of claim 1 , wherein the cells or cell lines are derived from human tissues and are directed to cancer cells, pancreatic beta cells, colonic epithelial cells, white blood cells, macrophages, immune cells, or liver cells, or other human cell types.

10. A method for screening cancer cells for polyamine transport activity comprising:
contacting a plurality of cells within each of a plurality of distinct cell lines with a fluorescent cyano-substituted anthracene probe selected from the group consisting of compound 3 and compound 4

incubating the cells and the probe for a time sufficient for the probe to be internalized within the cells;
exciting the probe using a visible light source; and
quantifying an amount of internalized probe within each of the cell lines.

11. The method of claim 10 , wherein at least one of the cell lines is a cell line having known polyamine transport activity.

12. The method of claim 11 , wherein the standard cell line comprises CHO-K1 cell line.

13. The method of claim 10 , wherein at least one of the cell lines is a cancer cell line.

14. The method of claim 10 , wherein the method is conducted via a high throughput screening process.

15. The method of claim 10 , further comprising washing the cells to remove unbound probe after the contacting step.

16. The method of claim 10 , wherein the cell lines are derived from human tissue.

17. A method of screening for therapeutic drug candidates that modulate uptake of polyamines in cells, said method comprising
incubating a cell having active polyamine uptake and a fluorescent cyano-substituted anthracene probe for a time sufficient for the probe to be internalized within the cell, wherein said incubating occurs within the presence of a therapy test compound;
exciting the probe using a visible light source; and
determining whether the probe is internalized by the at least one test cell;
wherein a test compound that modulates uptake of the probe into the cell is identified as a therapeutic drug candidate;

wherein said probe is compound 3 or 4

18. The method of claim 17 , wherein modulation of uptake of the probe comprises increasing or decreasing uptake of the probe.

Assignees

• Univ Central Florida Res Found

Inventors

• Phanstiel Iv Otto

Classifications

• G01N33/575

  for cancer · CPC title

• G01N33/5008

  for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title

• G01N21/6486 Primary

  Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence) · CPC title

• C07C255/58 Primary

  containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton · CPC title

• G01N33/533

  with fluorescent label · CPC title